-+ 0.00%
-+ 0.00%
-+ 0.00%

Fusion Antibodies Lands New Affinity Engineering Deal with European Client

MT Newswires·11/06/2026 04:48:42
Listen to the news
04:48 AM EST, 11/06/2026 (MT Newswires) -- Fusion Antibodies (FAB.L) secured an affinity engineering contract from a listed European global pharmaceutical company, according to a Friday release. The British preclinical antibody discovery company will use its proprietary Rational Affinity Maturation Programme technology to engineer the client's lead antibody under the project, which falls within an existing master services agreement. The project is expected to generate over 45,000 pounds sterling in revenue and be completed in the current financial year.